Reduce the Rate of SSI up to 65%
On the same occasion, Joice Simanjuntak, Essity Marketing Director, explained that Sorbact technology for wound care can prevent AMR. “Sorbact binds the microbe by a purely physical mechanism of action so that the microbe becomes inactive and removes it without killing it. Research proves that this mechanism does not lead to AMR. Sorbact technology used in our wound dressings, namely, Cutimed and Leukoplast. Unlike other antimicrobial dressings which actively kill microbes, these wound dressings are made of DACC which is hydrophobic, binds several types of microbes permanently, and reduces the number of organisms on the wound surface, so that wound healing is faster,” she said.
Read: Your lungs for life – beware of CPOD
Sorbact is able to reduce the rate of Surgical Wound Infection (SSI) up to 65%, compared to standard dressings, and is even able to bind 5 main WHO pathogenic bacteria, has no contraindications and a low risk of allergies, so it can be used in newborns, pregnant and lactating women, as well as patients with postoperative and chronic wounds, such as diabetic foot wounds and pressure sores resulting from bed rest. Sorbact technology uses an innovative approach to reduce bioburden in wounds without any chemically active agents, which may help cut the excessive use of antibiotics and improve a patient’s quality of life. They and have been registered on National Health Insurance (“BPJS Kesehatan”) since 2015. (est)